News | February 10, 2026
GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Angelini Ventures has already invested €125 million in 22 startups
Subscribe To Our Newsletter & Stay Updated
